ALK-Rearranged NSCLC With Brain Metastases Shows Prolonged Survival

Patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain metastases survive longer when treated with radiotherapy and tyrosine kinase inhibitors, according to a new study. The results suggest control of intracranial disease is important in these patients.

Cancer Network